Heterogeneity for IGF-II production maintained by public goods dynamics in neuroendocrine pancreatic cancer

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 6, 2015, Pages 1833-1838

  Archetti, Marco ^a   Ferraro, Daniela A ^b   Christofori, Gerhard ^b  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN B;

ANIMAL CELL; ARTICLE; CANCER CELL; CANCER GROWTH; CELL HETEROGENEITY; CELL POPULATION; CELL PROLIFERATION; CONTROLLED STUDY; COST BENEFIT ANALYSIS; FREQUENCY DEPENDENT SELECTION; GAME; IN VITRO STUDY; MOLECULAR DYNAMICS; MOUSE; NEUROENDOCRINE TUMOR; NONHUMAN; PANCREAS CANCER; PREDICTION; PRIORITY JOURNAL; ANIMAL; BIOLOGICAL MODEL; CELL LINEAGE; COMPUTER SIMULATION; DRUG EFFECTS; EVOLUTION; FLOW CYTOMETRY; GENETIC SELECTION; GENETICS; INSULINOMA; KNOCKOUT MOUSE; METABOLISM; PANCREAS TUMOR;

ANIMALS; BIOLOGICAL EVOLUTION; CELL LINEAGE; CELL PROLIFERATION; COMPUTER SIMULATION; FLOW CYTOMETRY; GAME THEORY; GAMES, EXPERIMENTAL; INSULIN-LIKE GROWTH FACTOR II; INSULINOMA; MICE; MICE, KNOCKOUT; MODELS, BIOLOGICAL; PANCREATIC NEOPLASMS; SELECTION, GENETIC;

EID: 84922681704     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1414653112     Document Type: Article

References (36)

1. Cairns J (1975) Mutation selection and the natural history of cancer. Nature 255(5505): 197-200.
2. Nowell PC (1976) The clonal evolution of tumor cell populations. Science 194(4260):23-28.
3. Merlo LMF, Pepper JW, Reid BJ, Maley CC (2006) Cancer as an evolutionary and ecological process. Nat Rev Cancer 6(12):924-935.
4. Greaves M, Maley CC (2012) Clonal evolution in cancer. Nature 481(7381):306-313.
5. Greenman C, et al. (2007) Patterns of somatic mutation in human cancer genomes. Nature 446(7132):153-158.
6. Navin N, et al. (2011) Tumour evolution inferred by single-cell sequencing. Nature 472(7341):90-94.
7. Dexter DL, Leith JT (1986) Tumor heterogeneity and drug resistance. J Clin Oncol 4(2): 244-257.
8. Maley CC, et al. (2006) Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet 38(4):468-473.
9. Almendro V, Marusyk A, Polyak K (2013) Cellular heterogeneity and molecular evolution in cancer. Annu Rev Pathol 8:277-302.
10. Axelrod R, Axelrod DE, Pienta KJ (2006) Evolution of cooperation among tumor cells. Proc Natl Acad Sci USA 103(36):13474-13479.
11. Cleary AS, Leonard TL, Gestl SA, Gunther EJ (2014) Tumour cell heterogeneity maintained by cooperating subclones in Wnt-driven mammary cancers. Nature 508(7494): 113-117.
12. Kim S, Goel S, Alexander CM (2011) Differentiation generates paracrine cell pairs that maintain basaloid mouse mammary tumors: Proof of concept. PLoS ONE 6(4):e19310.
13. West SA, et al. (2007) The social lives of microbes. Annu Rev Ecol Evol Syst 38:53-77.
14. Lee HH, Molla MN, Cantor CR, Collins JJ (2010) Bacterial charity work leads to pop-ulation-wide resistance. Nature 467(7311):82-85.
15. Gore J, Youk H, van Oudenaarden A (2009) Snowdrift game dynamics and facultative cheating in yeast. Nature 459(7244):253-256.
16. Christofori G, Naik P, Hanahan D (1994) A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis. Nature 369(6479):414-418.
17. Lamm GM, Christofori G (1998) Impairment of survival factor function potentiates chemotherapy-induced apoptosis in tumor cells. Cancer Res 58(4):801-807.
18. Burtscher I, Christofori G (1999) The IGF/IGF-1 receptor signaling pathway as a potential target for cancer therapy. Drug Resist Updat 2(1):3-8.
19. Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8(12):915-928.
20. Hanahan D (1985) Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 315(6015): 115-122.
21. Maynard Smith J (1982) Evolution and the Theory of Games (Cambridge Univ Press, Cambridge, UK).
22. Hardin G (1968) The tragedy of the commons. The population problem has no technical solution; it requires a fundamental extension in morality. Science 162(3859): 1243-1248.
23. Archetti M, Scheuring I (2012) Review: Game theory of public goods in one-shot social dilemmas without assortment. J Theor Biol 299:9-20.
24. Valenzano KJ, Heath-Monnig E, Tollefsen SE, Lake M, Lobel P (1997) Biophysical and biological properties of naturally occurring high molecular weight insulin-like growth factor II variants. J Biol Chem 272(8):4804-4813.
25. Nowak MA, Tarnita CE, Antal T (2010) Evolutionary dynamics in structured populations. Phil Trans R Soc Lond B Biol Sci 365(1537):19-30.
26. Perc M, Gómez-Gardeñes J, Szolnoki A, Floría LM, Moreno Y (2013) Evolutionary dynamics of group interactions on structured populations: A review. J R Soc Interface 10(80):20120997.
27. Gibson WT, Gibson MC (2009) Cell topology, geometry, and morphogenesis in proliferating epithelia. Curr Top Dev Biol 89:87-114.
28. Jouanneau J, Moens G, Bourgeois Y, Poupon MF, Thiery JP (1994) A minority of carcinoma cells producing acidic fibroblast growth factor induces a community effect for tumor progression. Proc Natl Acad Sci USA 91(1):286-290.
29. th Ed.
30. Karey KP, Sirbasku DA (1988) Differential responsiveness of human breast cancer cell lines MCF-7 and T47D to growth factors and 17 beta-estradiol. Cancer Res 48(14): 4083-4092.
31. Jourdan M, et al. (2005) Delineation of the roles of paracrine and autocrine inter-leukin-6 (IL-6) in myeloma cell lines in survival versus cell cycle. A possible model for the cooperation of myeloma cell growth factors. Eur Cytokine Netw 16(1):57-64.
32. Lambert G, et al. (2011) An analogy between the evolution of drug resistance in bacterial communities and malignant tissues. Nat Rev Cancer 11(5):375-382.
33. Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8(8):592-603.
34. Bozic I, et al. (2013) Evolutionary dynamics of cancer in response to targeted combination therapy. eLife 2:e00747.
35. Aktipis CA, Kwan VS, Johnson KA, Neuberg SL, Maley CC (2011) Overlooking evolution: A systematic analysis of cancer relapse and therapeutic resistance research. PLoS ONE 6(11):e26100.
36. Archetti M (2013) Evolutionarily stable anti-cancer therapies by autologous cell defection. Evol Med Public Health 2013(1):161-172.